Who is sponsoring NCT04697290?

NCT04697290 is sponsored by Beijing Tsinghua Chang Gung Hospital.

What drugs are being tested in NCT04697290?

Interventions in NCT04697290: CD19/CD20 Dual-CAR-T cells.

What condition does NCT04697290 study?

NCT04697290 studies B-cell Non-Hodgkin's Lymphoma.

Is NCT04697290 still recruiting?

NCT04697290 is currently suspended. Last updated 14 February 2022.

Last reviewed 2022-02-14 · How we verify

NCT04697290

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

Suspended EARLY_PHASE1 Last updated 14 February 2022

What this trial tests

EARLY_PHASE1 trial testing CD19/CD20 Dual-CAR-T cells in B-cell Non-Hodgkin's Lymphoma in 12 participants. Suspended.

Timeline

10 March 2022

Primary endpoint
10 March 2023

10 June 2023

Quick facts

Lead sponsor	Beijing Tsinghua Chang Gung Hospital
Phase	EARLY_PHASE1
Status	Suspended
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	10 March 2022
Primary completion	10 March 2023
Estimated completion	10 June 2023
Sites	1 location across China

Drugs / interventions tested

CD19/CD20 Dual-CAR-T cells — full drug profile →

Conditions studied

B-cell Non-Hodgkin's Lymphoma — all drugs for B-cell Non-Hodgkin's Lymphoma →

Sponsor

Beijing Tsinghua Chang Gung Hospital

Who can join

Adults 1 to 80, any sex, with B-cell Non-Hodgkin's Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory or relapsed B-NHL.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
Qin H, Zhou Z, Shi R, Mai Y, et al · · 2025 · cited 15× · PMID 40483473 · DOI 10.1186/s13045-025-01701-6
A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma.
Atrash S, Moyo TK. · · 2021 · cited 11× · PMID 33814917 · DOI 10.2147/ott.s242018

Verify or expand the search:

Other trials of CD19/CD20 Dual-CAR-T cells

Trials testing the same drug.

NCT04260945 — CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients · Phase 1 · completed
NCT04260932 — CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients · Phase 1 · completed

Other recruiting trials for B-cell Non-Hodgkin's Lymphoma

Currently open trials in the same condition.

NCT07081022 — JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting
NCT05436223 — Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting

Other Beijing Tsinghua Chang Gung Hospital trials

Trials by the same sponsor.

NCT07123675 — AI-Assisted Blood Pressure Control During Anesthesia · NA · not yet recruiting
NCT07152496 — Host-Microbe Interactions in Biliary Dilatation · not yet recruiting
NCT07330271 — PTC-Guided Therapy for Peritoneal Mesothelioma · NA · recruiting
NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei · NA · recruiting
NCT07044947 — Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC） · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04697290 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Tsinghua Chang Gung Hospital
Last refreshed: 14 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04697290.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing